( NASDAQ:CYTR )

News from CytRx Corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 17, 2017, 09:00 ET CytRx Corporation Regains Nasdaq Listing Compliance

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it received...


Nov 13, 2017, 09:00 ET CytRx Corporation Provides Business Update and Announces New Shareholder Initiatives

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today provided a business update...


Nov 08, 2017, 09:00 ET CytRx Reports Third Quarter 2017 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results...


Nov 06, 2017, 09:00 ET CytRx Announces Strategic Realignment of Clinical Development Team

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the strategic...


Nov 02, 2017, 09:00 ET CytRx Corporation Highlights Recent Progress at Freiburg, Germany, Laboratory and Provides Update for Oncology Pipeline

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted recent progress...


Oct 31, 2017, 09:00 ET CytRx Corporation Announces Reverse Stock Split

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the previously...


Oct 27, 2017, 14:15 ET CytRx Corporation Announces Results from Special Meeting of Stockholders

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the results of the...


Oct 16, 2017, 18:23 ET CytRx Corporation Announces Outcome of Nasdaq Hearing

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Nasdaq has...


Oct 12, 2017, 09:00 ET CytRx Corporation Highlights Inclusion of Aldoxorubicin in Pending Upcoming Clinical Trial Submissions Planned By Licensee NantCell, Inc.

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that...


Oct 04, 2017, 09:00 ET Institutional Shareholder Services, Inc., Recommends CytRx Corporation Stockholders Vote "FOR" the Proposed Reverse Stock Split

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Institutional...


Oct 02, 2017, 09:00 ET CytRx Corporation Provides Business Update and Highlights Future Plans

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today provided a business update...


Sep 21, 2017, 09:00 ET Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends CytRx Corp. Stockholders Vote "FOR" the Proposed Reverse Stock Split

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Glass Lewis...


Sep 13, 2017, 09:00 ET CytRx Corporation Announces Amendment to Definitive Proxy Statement for Upcoming Special Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that based on...


Aug 30, 2017, 09:00 ET CytRx Corporation Files Definitive Proxy Statement for Upcoming Special Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has filed...


Aug 24, 2017, 09:00 ET CytRx Corporation Announces Receipt of NASDAQ Listing Determination

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that, as...


Aug 21, 2017, 09:00 ET CytRx Corporation Files Preliminary Proxy Statement for Upcoming Special Meeting

CytRx Corporation (NASDAQ: CYTR) ("CytRx or "the Company"), a biopharmaceutical research and development company specializing in oncology,...


Aug 03, 2017, 09:00 ET CytRx Reports Second Quarter 2017 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results...


Jul 28, 2017, 09:00 ET CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has...


Jun 13, 2017, 09:00 ET CytRx Announces Reshaping of Clinical and Regulatory Executive Team

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Shanta...


Jun 08, 2017, 09:00 ET CytRx Announces Update on the Regulatory Pathway for Aldoxorubicin in Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR) a biopharmaceutical research and development company specializing in oncology, today announced an update on the...


May 17, 2017, 17:04 ET CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the presentation...


May 10, 2017, 09:00 ET CytRx Reports First Quarter 2017 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results...


Apr 28, 2017, 07:51 ET CytRx Corporation Announces Pricing of $15 Million Public Offering of Common Stock

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has priced...


Apr 27, 2017, 17:55 ET CytRx Corporation Announces Proposed Public Offering of Common Stock

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology today announced a proposed public...


Apr 19, 2017, 07:00 ET CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR) today announced the U.S. Food and Drug Administration (FDA) has reached an agreement with CytRx on preparations...